We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

MIF

MIF inhibitors target macrophage migration inhibitory factor, a cytokine with an enzymatic pocket. Macrophage migration inhibitory factor (MIF) was described in 1966 as a lymphocyte product that inhibits macrophage migration in delayed-type hypersensitivity. In 1996, the trimeric protein was found to catalyze a tautomerization reaction. A 2003 study showed that MIF signals by binding to the cell surface protein cluster of differentiation 74 (CD74). 4-IPP and ISO-92 are listed as MIF inhibitors, and MIF098 and (±)-CPSI-1306 as MIF antagonists. MD13 is a proteolysis-targeting chimera (PROTAC) that induces degradation of MIF in cells. 4-CPPC acts on the homolog MIF-2, also called D-dopachrome tautomerase. The set also contains (E/Z)-BCI, a dual-specificity phosphatase 6 (DUSP6) inhibitor.

2 Items

  • (±)-CPSI-1306
    Cat. No.
    A19875
    CAS No.
    1309793-47-2

    (±)-CPSI-1306

    Synonyms: CPSI1306

    (±)-CPSI-1306 is an orally available antagonist of macrophage migration inhibitory factor (MIF).

    In stock View Details
    5 mg
    $20.00
    10 mg
    $30.00
    All 7 sizes
  • MIF098
    Cat. No.
    A64997
    CAS No.
    1208448-95-6

    MIF098

    MIF098 is a potent macrophage migration inhibitory factor (MIF) antagonist. It effectively inhibits the proliferation, migration, and fibrosis of pulmonary smooth muscle cells, making it a valuable tool in the study of immunoinflammatory diseases. Research applications include investigating mechanisms of pulmonary disorders and exploring potential therapeutic strategies for related conditions.

    In stock View Details
    1 mg
    $35.00
    5 mg
    $80.00
    All 6 sizes

2 Items

Added to your cart

View Cart Checkout

    Loading...